Join a team of brilliant, passionate innovators determined to transform healthcare. At BillionToOne, we've built a category-defining, publicly traded company on Nasdaq where transparency fuels trust, collaboration drives breakthroughs, and every contribution moves the needle on our mission to make life-changing diagnostics accessible to all. We don't just aim for incremental improvements; we build products that are 10x better than anything that exists today.
With over 700 employees, half a million patients helped, and one of the most successful IPOs in medical diagnostics history behind us, we're just getting started. Our scientists, engineers, sales executives, and visionaries are united by an unwavering commitment to changing the standard of care in prenatal and cancer diagnostics. This is where cutting-edge science meets human compassion, and every innovation you contribute helps remove the fear of the unknown from some of life's most critical medical moments.
If you're driven by purpose, energized by innovation, and ready to help shape the future of precision medicine at scale, this is where you belong.
BillionToOne is seeking a Scientist or Senior Scientist focused on Real-World Data (RWD) and Clinical AI to help unlock insights from our rapidly growing dataset of genomic profiles and real-world clinical data.
This role sits at the intersection of AI, genomics, oncology research, and clinical data science. The scientist will develop models and analytical approaches that transform genomic and clinical data into actionable insights for research, clinical decision support, and future data-driven products.
A unique aspect of this role is the opportunity to work with BillionToOne’s proprietary dataset, combining genomic sequencing results from our Northstar oncology platform with real-world medical records. Leveraging this rich dataset, the scientist will generate clinically meaningful insights and real-world evidence (RWE) to improve treatment decisions and advance precision oncology. This role will report to the Chief Product Officer.
Leverage BillionToOne’s integrated datasets of Northstar genomic sequencing results and real-world clinical data from patients we serve to generate clinically meaningful insights and real-world evidence (RWE). Develop AI and machine learning approaches that uncover patterns across genomic alterations, treatment histories, and patient outcomes, supporting internal research and improving how genomic test results inform clinical decision-making.
Develop AI-powered tools that enhance the clinical utility of BillionToOne’s diagnostics, including systems that surface relevant medical records, literature evidence, clinical trials, and guideline information alongside Northstar test results to assist oncologists in making more personalized treatment decisions. The role will also build AI tools that support internal scientific operations—such as literature discovery, variant interpretation, and clinical trial or guideline tracking—while helping lay the foundation for future real-world data products leveraging BillionToOne’s unique genomics and clinical dataset for pharmaceutical and research partners.
Experience:
For more information about how we protect your information, we encourage you to review our Privacy Policy.
BillionToOne is a next-generation molecular diagnostics company on a mission to make powerful, accurate diagnostic tests accessible to everyone. Our revolutionary QCT molecular counting technology enhances disease detection resolution by over a thousandfold using cell-free DNA,a breakthrough that has already transformed the lives of over half a million patients worldwide.
Unity Complete™ is the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Our Northstar® liquid biopsy test uniquely combines treatment selection with real-time monitoring, giving oncologists unprecedented precision in cancer care.
From $0 to $150M+ in Annual Recurring Revenue in just five years. In 2025, we completed one of the most successful IPOs for a medical diagnostics company, building on nearly $400M in private funding,including our $130M Series D in 2024 and backed by world-class investors including Hummingbird, Adams Street Partners, Neuberger Berman, Baillie Gifford, and Premji Invest.
Forbes named us one of America's Best Startup Employers for 2025 and we're Great Place to Work certified, with 100% of our people willing to go the extra mile, even as we've scaled to over 700 employees.
Headquartered in Menlo Park with facilities in Union City, CA, and a new lab opening in Austin, TX in 2027, we're continuing to push the boundaries of what's possible in molecular diagnostics. We're just getting started.
Ready to help us change the world, one molecule at a time? Learn more at billiontoone.com